Purple Biotech (PPBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Purple Biotech (PPBT) has a cash flow conversion efficiency ratio of -0.205x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.50 Million) by net assets ($12.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Purple Biotech worth for the company's overall valuation and market capitalisation.
Purple Biotech - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Purple Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Purple Biotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech ranked by their cash flow conversion efficiency. Explore Purple Biotech earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianci International, Inc. Common Stock
NASDAQ:CIIT
|
-0.002x |
|
Avrupa Minerals Ltd
V:AVU
|
-0.155x |
|
Magnetite Mines Ltd
AU:MGT
|
-0.030x |
|
Celtic plc
LSE:CCPA
|
-0.038x |
|
GoldOn Resources Ltd
V:GLD
|
-0.098x |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
0.073x |
|
Adiuvo Investment SA
WAR:ADV
|
-0.005x |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Purple Biotech (2013–2025)
The table below shows the annual cash flow conversion efficiency of Purple Biotech from 2013 to 2025. View PPBT share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.66 Million | $-5.54 Million | -0.573x | -31.31% |
| 2024-12-31 | $32.91 Million | $-14.37 Million | -0.437x | +24.86% |
| 2023-12-31 | $34.30 Million | $-19.93 Million | -0.581x | -63.50% |
| 2022-12-31 | $47.10 Million | $-16.73 Million | -0.355x | -51.69% |
| 2021-12-31 | $65.11 Million | $-15.25 Million | -0.234x | -54.50% |
| 2020-12-31 | $79.75 Million | $-12.09 Million | -0.152x | +70.49% |
| 2019-12-31 | $10.86 Million | $-5.58 Million | -0.514x | +33.32% |
| 2018-12-31 | $11.00 Million | $-8.48 Million | -0.771x | +23.24% |
| 2017-12-31 | $8.59 Million | $-8.63 Million | -1.004x | -114.60% |
| 2016-12-31 | $13.38 Million | $-6.26 Million | -0.468x | -33.35% |
| 2015-12-31 | $9.43 Million | $-3.31 Million | -0.351x | +94.01% |
| 2014-12-31 | $773.00K | $-4.53 Million | -5.855x | -1181.82% |
| 2013-12-31 | $-946.00K | $-512.00K | 0.541x | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more